vs
ASP Isotopes Inc.（ASPI）与凯特制药（NAMS）财务数据对比。点击上方公司名可切换其他公司
凯特制药的季度营收约是ASP Isotopes Inc.的1.1倍（$19.1M vs $16.7M），ASP Isotopes Inc.同比增速更快（1295.7% vs 740.1%），凯特制药自由现金流更多（$-37.8M vs $-47.4M）
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
凯特制药是一家美国生物技术企业，专注于研发癌症免疫治疗产品，核心方向为基因工程改造的自体嵌合抗原受体T细胞（CAR-T）疗法，这是一种基于嵌合抗原受体与T细胞的细胞治疗技术。公司成立于2009年，总部位于加利福尼亚州圣莫尼卡，2017年被吉利德科学收购。
ASPI vs NAMS — 直观对比
营收规模更大
NAMS
是对方的1.1倍
$16.7M
营收增速更快
ASPI
高出555.6%
740.1%
自由现金流更多
NAMS
多$9.7M
$-47.4M
损益表 — Q4 FY2025 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.7M | $19.1M |
| 净利润 | — | $-17.4M |
| 毛利率 | 12.5% | — |
| 营业利润率 | — | -186.1% |
| 净利率 | — | -90.7% |
| 营收同比 | 1295.7% | 740.1% |
| 净利润同比 | -586.8% | 55.5% |
| 每股收益（稀释后） | — | $-0.15 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPINAMS
| Q4 25 | $16.7M | — | ||
| Q3 25 | $4.9M | — | ||
| Q2 25 | — | $19.1M | ||
| Q4 24 | — | $12.8M | ||
| Q3 24 | — | $29.1M | ||
| Q2 23 | — | $8.6M |
净利润ASPINAMS
| Q4 25 | — | — | ||
| Q3 25 | $-12.9M | — | ||
| Q2 25 | — | $-17.4M | ||
| Q4 24 | — | $-92.2M | ||
| Q3 24 | — | $-16.6M | ||
| Q2 23 | — | $-42.0M |
毛利率ASPINAMS
| Q4 25 | 12.5% | — | ||
| Q3 25 | 8.7% | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 23 | — | — |
营业利润率ASPINAMS
| Q4 25 | — | — | ||
| Q3 25 | -306.1% | — | ||
| Q2 25 | — | -186.1% | ||
| Q4 24 | — | -338.5% | ||
| Q3 24 | — | -85.9% | ||
| Q2 23 | — | -461.8% |
净利率ASPINAMS
| Q4 25 | — | — | ||
| Q3 25 | -263.7% | — | ||
| Q2 25 | — | -90.7% | ||
| Q4 24 | — | -721.7% | ||
| Q3 24 | — | -57.2% | ||
| Q2 23 | — | -486.9% |
每股收益（稀释后）ASPINAMS
| Q4 25 | — | — | ||
| Q3 25 | $-0.15 | — | ||
| Q2 25 | — | $-0.15 | ||
| Q4 24 | — | $-0.91 | ||
| Q3 24 | — | $-0.18 | ||
| Q2 23 | — | $-0.51 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $333.3M | $739.2M |
| 总债务越低越好 | $14.4M | — |
| 股东权益账面价值 | $204.2M | $778.5M |
| 总资产 | $498.0M | $815.1M |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资ASPINAMS
| Q4 25 | $333.3M | — | ||
| Q3 25 | $113.9M | — | ||
| Q2 25 | — | $739.2M | ||
| Q4 24 | — | $834.2M | ||
| Q3 24 | — | $422.7M | ||
| Q2 23 | — | — |
总债务ASPINAMS
| Q4 25 | $14.4M | — | ||
| Q3 25 | $13.9M | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 23 | — | — |
股东权益ASPINAMS
| Q4 25 | $204.2M | — | ||
| Q3 25 | $74.1M | — | ||
| Q2 25 | — | $778.5M | ||
| Q4 24 | — | $757.5M | ||
| Q3 24 | — | $378.9M | ||
| Q2 23 | — | $398.4M |
总资产ASPINAMS
| Q4 25 | $498.0M | — | ||
| Q3 25 | $225.9M | — | ||
| Q2 25 | — | $815.1M | ||
| Q4 24 | — | $864.6M | ||
| Q3 24 | — | $439.2M | ||
| Q2 23 | — | — |
负债/权益比ASPINAMS
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.8M | $-37.7M |
| 自由现金流经营现金流 - 资本支出 | $-47.4M | $-37.8M |
| 自由现金流率自由现金流/营收 | -284.7% | -197.2% |
| 资本支出强度资本支出/营收 | 57.9% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-119.7M |
8季度趋势，按日历期对齐
经营现金流ASPINAMS
| Q4 25 | $-37.8M | — | ||
| Q3 25 | $-8.9M | — | ||
| Q2 25 | — | $-37.7M | ||
| Q4 24 | — | $-37.5M | ||
| Q3 24 | — | $-12.5M | ||
| Q2 23 | — | $-31.9M |
自由现金流ASPINAMS
| Q4 25 | $-47.4M | — | ||
| Q3 25 | $-12.0M | — | ||
| Q2 25 | — | $-37.8M | ||
| Q4 24 | — | $-37.5M | ||
| Q3 24 | — | $-12.6M | ||
| Q2 23 | — | $-31.9M |
自由现金流率ASPINAMS
| Q4 25 | -284.7% | — | ||
| Q3 25 | -245.5% | — | ||
| Q2 25 | — | -197.2% | ||
| Q4 24 | — | -293.5% | ||
| Q3 24 | — | -43.2% | ||
| Q2 23 | — | -369.3% |
资本支出强度ASPINAMS
| Q4 25 | 57.9% | — | ||
| Q3 25 | 64.4% | — | ||
| Q2 25 | — | 0.5% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 23 | — | 0.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
